Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: DelMar Takes On Unmet Need In Brain Cancer With Accurexa

Executive Summary

Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.

You may also be interested in...



GW Pharma High On Epilepsy Results, Plans 2017 NDA

The biotech announces another set of positive anti-seizure results for its marijuana-derived product.

PIPELINE WATCH - Four Launches, Two Approvals And Six Orphan Drug Designations

The table records clinical and regulatory developments using data from BioMedTracker. It lists all drugs for which an event was recorded from April 15 to April 21, 2016, divided by event type.

AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid

Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC097268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;